DSA Intragraft in Lung Transplantation: Diagnostic and Prognostic Value in Antibody Mediated Rejection

Inclusion criteria: * Patient older than 18 years * Transplanted pulmonary or cardiopulmonary patient * And developing circulating anti-HLA antibodies directed against the graft or "DSA" at a threshold \> 1000 of MFI in the 30 days preceding the inclusion visit * Affiliation to the French social security * Patient able to understand the objectives and risks related to research and to give informed, dated and signed consent Exclusion criteria: * Patient whose anti-HLA antibodies are not directed against the graft (no DSA) * Contraindication to performing a bronchial fibroscopy with transbronchial biopsies * Treatment with intravenous immunoglobulin (less than 1 month before inclusion) or Rituximab (less than 6 months before inclusion) * Plasma exchanges (less than 3 months before inclusion) * Risk of bleeding predictable (crushing disorder, impossibility of stopping the offending treatments) * Impossibility of giving the subject informed information * Subject under the protection of justice Subject under guardianship or curatorship * Pregnancy * Breastfeeding